| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032730 Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032721 Methods of administering dalbavancin for treatment of skin and soft tissue infections |
| 02/10/2005 | US20050032716 controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests on domestic animals; contains a synergistic combination of a A83543 compound and a macrocyclic lactone |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032704 Neural thread proteins (NTP); antiproliferative agents |
| 02/10/2005 | US20050032679 Process for the preparation of echinocandin derivatives |
| 02/10/2005 | US20050032676 Administering lipidated glycopeptide antibiotic and cyclodextrin, reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032047 Comprises peptide for genotyping and detecting hepatitis viral infection; immunoassay |
| 02/10/2005 | US20050032044 Lipid and cryoprotectant; gene therapy |
| 02/10/2005 | US20050032039 HIV-specific T-cell induction |
| 02/10/2005 | US20050032038 Methods of identifying anti-viral agents |
| 02/10/2005 | US20050032036 Using drug resistant bacterial strains as tools for identifying bactericidal phage; preventing staphylococcus infection |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031646 Immunogens; polysaccharide conjugate antigens derived from pathogenic bacterium conjugated to protein D from Haemophilus influenzae |
| 02/10/2005 | US20050031644 Modifying wild strain of enteroinvasive Shigella; cannot spread within infected cells and from infected to uninfected cells of the host; vaccines; deactivation by inserting transposon into gene; mutagenizing; genetically engineered by allelic exchange |
| 02/10/2005 | US20050031636 Papilloma virus capsomere vaccine formulations and methods of use |
| 02/10/2005 | US20050031628 Chimeric antigens for breaking host tolerance to foreign antigens |
| 02/10/2005 | US20050031625 First antibody binds CR1 receptor coupled to second antibody that binds to protective antigen component of anthrax toxin, but does not inhibit the binding of the protective antigen component of the anthrax toxin to cells |
| 02/10/2005 | US20050031613 CD 16 antigen; antibody produced by cell unresistant to lectin which recognizes sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain; signal transduction |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031601 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 02/10/2005 | US20050031589 Method of treating hepatitis C infection |
| 02/10/2005 | US20050031586 Method for treating hepatitis c virus infection in treatment failure patients |
| 02/10/2005 | US20050031585 Treating individuals having hepatitis C virus infection, who have failed to respond to therapy with IFN-alpha other than consensus interferon (CIFN), or who, following cessation of therapy with IFN-alpha other than CIFN, have suffered relapse by administering first, then second dosing CIFN, and ribavirin |
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050031577 Therapeutic polyesters and polyamides |
| 02/10/2005 | US20050030912 Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field |
| 02/10/2005 | CA2534649A1 Bicyclic imidazol derivatives against flaviviridae |
| 02/10/2005 | CA2533918A1 Use of adcc-optimized antibodies for treating weak patients |
| 02/10/2005 | CA2533506A1 Thio-substituted phenbutazone compounds as anti-inflammatory, anti-viral and immunomodulatory agents |
| 02/10/2005 | CA2533150A1 A doxycycline metal complex in a solid dosage form |
| 02/10/2005 | CA2532965A1 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 02/10/2005 | CA2531684A1 Binding molecules against sars-coronavirus and uses thereof |
| 02/09/2005 | EP1505153A1 Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1504754A1 Gallocatechin gallate-containing composition |
| 02/09/2005 | EP1504112A2 Development of a preventive vaccine for filovirus infection in primates |
| 02/09/2005 | EP1504095A2 Site specific listeria integration vectors and methods for using the same |
| 02/09/2005 | EP1504088A2 Bacteriophages useful for therapy and prophylaxis of bacterial infections |
| 02/09/2005 | EP1504040A1 Method for reduction of residual organic solvent in carbomer |
| 02/09/2005 | EP1504036A2 Toxin-related antibodies with antimicrobial and antiviral activity |
| 02/09/2005 | EP1504014A2 Process for preparation of cyclic prodrugs of pmea and pmpa |
| 02/09/2005 | EP1504004A2 Substituted pyrazolopyrimidines |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503981A2 Substituted tetracycline compounds |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503793A2 Cancer vaccines and methods of using the same |
| 02/09/2005 | EP1503792A2 Attenuation of metapneumovirus |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503784A2 Treatment and inhibition of ocular infections and wounds by cap37 and cap37 peptides |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503772A1 Soluble composition containing sporopollenin and the use thereof |
| 02/09/2005 | EP1503769A1 Antibiotic/benzoyl peroxide dispenser |
| 02/09/2005 | EP1503762A2 Novel crystalline forms of gatifloxacin |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503741A2 Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1503737A1 Nanoparticulate nystatin formulations |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1390031B1 Topical composition containing a fungicide |
| 02/09/2005 | EP1349839B1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/09/2005 | EP1299059A4 Method and manufacture of a wound dressing for covering an open wound |
| 02/09/2005 | EP1296703B1 Non-antibacterial tetracycline as anti-fungal agents |
| 02/09/2005 | EP1294705A4 Synthesis of cyclic compounds |
| 02/09/2005 | EP1280535B1 Processes for preparing clarithromycin polymorphs |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1191924A4 Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
| 02/09/2005 | EP1165054A4 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1140939B1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods |
| 02/09/2005 | EP1111995B1 Topical dermal antimicrobial compositions |
| 02/09/2005 | EP1082875A4 Improved brush block housing for propeller deicing system |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP1042316B1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 02/09/2005 | EP0957927B1 Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation |
| 02/09/2005 | EP0900210B1 Antivirally active heterocyclic azahexane derivatives |
| 02/09/2005 | EP0843818B1 Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents |
| 02/09/2005 | EP0383799B2 Adheson variants |
| 02/09/2005 | CN1578840A Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578785A Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578676A Lox concentration of peroxide for treating or preventing vaginal infections |
| 02/09/2005 | CN1578672A Rsv基因表达疫苗 Rsv gene expression vaccine |
| 02/09/2005 | CN1578670A Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578650A Compositions for the treatment of infectious diseases |
| 02/09/2005 | CN1578626A Multivesicular emulsion topical delivery systems |
| 02/09/2005 | CN1575815A Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 02/09/2005 | CN1575814A Medicinal composition for eyes, it's preparing process and use thereof |
| 02/09/2005 | CN1575813A Preparation for eyes and preparing method thereof |
| 02/09/2005 | CN1575808A Medicine for treating hepatitis B and hepatic ascites and preparation and using method thereof |